Lundbeck chair exits as company seeks calm

Denmark's troubled H. Lundbeck, which has been roiled by the failure of two late-stage trials and a delayed rollout of a U.S. sales force, is bidding goodbye to its chairman. Flemming Lindeløv's departure comes as a gesture to "restore calm," says the company. But with two big patents expiring in 2012 and 2014, analysts are looking for more success on the development side. Lundbeck has been under considerable pressure to acquire new therapies or find a bigger pharma company to merge with.

- see this release for more

Related Articles:
Merck, Lundbeck end gaboxadol development. Report
Teva, H. Lundbeck stop work on oral Copaxone. Report
Lundbeck's shares plunge as drug flunks Phase III. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.